Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$126.59 ▲ +0.07
(+0.06%)
MKT CAP: $4.30B • VOL: 571.7K
52W L $66 52W H $127
ITGR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.85B | $1.72B | $1.56B |
| YoY Revenue Growth % | +8.0% | +10.3% | — |
| Gross Profit | $500.4M | $459.0M | — |
| Gross Margin % | 27.0% | 26.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $221.3M | $208.2M | $163.3M |
| Operating Margin % | 11.9% | 12.1% | 10.5% |
| Net Income (GAAP) | $102.8M | $119.9M | $90.7M |
| EBITDA (Normalized) | $294.1M | $292.5M | $219.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $196.1M | $205.2M | $180.2M |
| Capital Expenditures (CapEx) | $91.0M | $105.4M | $70.0M |
| Free Cash Flow (FCF) | $105.1M | $99.8M | $110.2M |
| FCF Margin % | 5.7% | 5.8% | 7.1% |
| Return on Invested Capital (ROIC %) | 6.0% | 6.4% | 9.0% |
| Cash & Short-Term Equivalents | $17.2M | $46.5M | — |
| Total Debt (Short + Long Term) | $1.19B | $980.2M | $553.5M |
| Total Stockholders' Equity | $1.75B | $1.62B | $1.14B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ITGR.